AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

Table 1 Prevalence of the AKT1 ^E17K mutation in untreated (UICC stages I–IV), neoadjuvantly treated, or relapsed breast cancer patients

	Total n	AKT1 ^E17K n (%)	Wild type n (%)	95 % CI
Neoadjuvant^a	79	5 (6.3)	74 (93.7)	2.1–14.2
Relapsed^b	46	5 (10.9)	41 (89.1)	3.6–23.6
UICC stages I–IV^a	494	29 (5.9)	465 (94.1)	4.0–8.3
Overall	619	39 (6.3)	580 (93.7)	4.5–8.5

DNA was obtained from fresh frozen tumor tissue and analyzed using BEAMing
^aER-positive patients
^bER-positive and ER-negative patients
Abbreviations: 95 % CI 95 % exact confidence interval, AKT1 v-akt murine thymoma viral oncogene, ER estrogen receptor, UICC Union for International Cancer Control

ISSN: 1471-2407